CAPLACIZUMAB-YHDP INJ,LYPHL
Clinical Criteria Summary
Exclusion Criteria
- Congenital Thrombotic Thrombocytopenic Purpura
- Concurrent antiplatelet agents or anticoagulants
- Active bleeding or history of bleeding disorder
- Platelet count greater than or equal to 100,000/uL
- Pregnancy
- Lactating
Inclusion Criteria
- Acquired/Immune Thrombotic Thrombocytopenic Purpura (iTTP) along with plasma exchange and immunosuppression
- ADAMTS13 activity <10% or pending
Additional Inclusion Criteria
- Care is provided by a VA/VA Community Care hematology or oncology provider
- Goals of care have been discussed and documented in the electronic health record
Discontinuation Criteria
- Stop caplacizumab when ADAMTS13 activity is >10% on 2 consecutive weeks or >30% on one occasion